FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
10 letters match. Newest first.
-
DrugsProRx LLC
ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.
High risk -
DrugsAmazing Meds
FDA warned online seller Amazing Meds over unapproved compounded retatrutide and a misleading "same as Ozempic/Wegovy" semaglutide claim.
High risk -
DrugsGLP-1 Solution
GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.
High risk -
DrugsEA WORKS Limited Liability Company dba Trust Labs
FDA warned Trust Labs it sold unapproved compounded retatrutide and made false FDA-approval claims for semaglutide and tirzepatide online.
High risk -
AnimalMeds For Vets, LLC
Meds For Vets compounded unapproved animal drugs from bulk substances and failed manufacturing quality rules, including sterility controls.
High risk -
AnimalBoothwyn Pharmacy LLC
FDA warns Boothwyn Pharmacy over unapproved compounded animal drugs and falsified endotoxin records.
High risk -
DrugsProRx, LLC
FDA warns ProRx, LLC about insanitary sterile compounded-drug production and manufacturing-quality failures.
High risk -
DrugsBelmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy
FDA warns Drug Depot dba APS Pharmacy over compounded drugs made with ineligible bulk substances.
Medium -
DrugsImprimis Rx LLC
FDA warns Imprimis Rx over false, misleading promotion of compounded eye drug Pred-Moxi-Brom.
Low -
DrugsPharmaceutical Care Solutions dba Pharmacy Solutions
FDA warns Pharmaceutical Care Solutions dba Pharmacy Solutions over compounded drugs made with ineligible bulk substances and lacking FDA approval.
Medium